AzTrials
AzTrials

InfertilityNCT00750451

Low Molecular Weight Heparin in Recurrent Implantation Failure

A study testing low molecular weight heparin (enoxaparine sodium) and crinone 8% gel in people with Infertility and Fertilization in Vitro, run by V.K.V. American Hospital, Istanbul at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments have been offered without substantial evaluation. Read more about this study

Who is it for?
Ages 18 to 38 years, women only
What is being tested?
low molecular weight heparin (enoxaparine sodium) and crinone 8% gel
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
Not given
Where
1 siteTurkey (Türkiye)
Study dates
Jan 2006to May 2008
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 38 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • History of at least two previously failed fresh embryo transfer cycles
  • All previously failed cycles to be performed in the American Hospital of Istanbul
  • Female age ≤ 38 years
  • Fresh ejaculate sperms to be used for ICSI
  • No hormonal, coagulation, or immunological disorders detected
  • Normal uterine cavity, as assessed by diagnostic office hysteroscopy or saline infusion sonography
  • Normal female and male peripheral karyotype

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Assisted Reproduction Unit of the American Hospital of Istanbul

    Istanbul, 34365

Other trials in Turkey (Türkiye)

About this study

Official title: Empirical Low Molecular Weight Heparin Administration in the Luteal Phase in Patients With Recurrent Implantation Failures: a Randomized Open Labeled Trial

Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments have been offered without substantial evaluation. Heparin is thought to play a role in the embryo implantation process beyond its anticoagulation effects. The proposed study aims to assess the effectiveness and safety of empirical administration of low molecular weight heparin in patients undergoing a new IVF treatment cycle after multiple failed attempts.

Being tested
low molecular weight heparin (enoxaparine sodium), crinone 8% gel
Keywords
fertilization in vitro, assisted reproduction, recurrent implantation failure, low molecular weight heparin, heparin, luteal phase
Medical subject headings
Infertility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • low molecular weight heparin (enoxaparine sodium)Drug

    1 mg/kg/day subcutaneously in the luteal phase after IVF treatment

  • crinone 8% gelDrug

    routine luteal phase support with progesterone gel

Study groups in NCT00750451
Study groupRoleWhat they receive
LMWHExperimentalWomen in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
Receives: Drug: low molecular weight heparin (enoxaparine sodium)
ControlActive comparatorWomen in the control arm are administered routine luteal phase support without the addition of LMWH
Receives: Drug: crinone 8% gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ongoing pregnancy beyond the 20th gestational week rate

Secondary outcomes (2)
  1. Clinical pregnancy rate

  2. Embryo implantation rate

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2008 (estimated)
  2. Study startJan 2006
  3. Primary completionMay 2008
  4. Study completionMay 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
IDs, dates and publications
ClinicalTrials.gov ID
NCT00750451
Sponsor's protocol ID
AH-05/11
Status last verified
Mar 2009
First submitted
9 Sep 2008
Last updated
20 Mar 2009
Results posted
No

Publications

  • Urman B, Ata B, Yakin K, Alatas C, Aksoy S, Mercan R, Balaban B. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod. 2009 Jul;24(7):1640-7. doi: 10.1093/humrep/dep086. Epub 2009 Apr 8.

    PubMed 19357135

Questions about this trial

What is this clinical trial studying?

A study testing low molecular weight heparin (enoxaparine sodium) and crinone 8% gel in people with Infertility and Fertilization in Vitro, run by V.K.V. American Hospital, Istanbul at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Mar 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ongoing pregnancy beyond the 20th gestational week rate. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00750451, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in